Daiichi Sankyo Company, Limited

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-05 am EDT			5-day change	1st Jan Change
2,490.00 ^JPY	+4.10%		-7.79%	-25.63%

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
May. 28	Daiichi Sankyo concludes pcpa letter of intent for Vanflyta®	RE

Daiichi Sankyo Company, Limited Reports Earnings Results for the Full Year Ended March 31, 2026

Published on 05/11/2026 at 02:30 am EDT

S&P Capital IQ

DAIICHI SANKYO COMPANY, LIMITED

+4.10%

Daiichi Sankyo Company, Limited reported earnings results for the full year ended March 31, 2026. For the full year, the company reported sales was JPY 2,123,045 million compared to JPY 1,886,256 million a year ago. Net income was JPY 259,874 million compared to JPY 295,756 million a year ago.

Basic earnings per share from continuing operations was JPY 140.44 compared to JPY 155.96 a year ago. Diluted earnings per share from continuing operations was JPY 140.37 compared to JPY 155.87 a year ago.

Latest news about Daiichi Sankyo Company, Limited

Jun. 05	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca	AN
May. 28	Daiichi Sankyo concludes pcpa letter of intent for Vanflyta®	RE
May. 28	Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO	CI
May. 26	AstraZeneca says Datroway approved in US for 1L triple-negative BC	RE
May. 22	FTSE 100 Closes Week Upbeat; AstraZeneca Sees Oncology Approval Progress	MT
May. 22	AstraZeneca Breast Cancer Drug Recommended for Approval by EU Regulator	DJ
May. 22	AstraZeneca and Daiichi cancer drugs clear regulatory hurdles	AN
May. 22	AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer	MT
May. 22	AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Wins US FDA Approval	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S	CI
May. 22	AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2-Positive Solid Tumors	MT
May. 22	AstraZeneca, Daiichi Sankyo Win EU Panel's Recommendation for Metastatic Solid Tumors Therapy	MT
May. 22	Daiichi Sankyo and Astrazeneca Announce Enhertu's Recommendation for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	CI
May. 22	EMA's CHMP recommends extension to marketing authorisation for Wegovy	RE
May. 21	Astrazeneca Receives CHMP Recommendation for Enhertu Approval in the Eu for Previously Treated Her2-Positive Metastatic Solid Tumours	CI

Chart Daiichi Sankyo Company, Limited

Duration

Period

4568: Dynamic Chart

Company Profile

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Employees

19,765

Sector

Pharmaceuticals

More about the company